Abiraterone and its place in the treatment of metastatic CRPC.

Abstract	An update of the COU-AA-301 study confirms a survival advantage with abiraterone–prednisone compared to prednisone in post-docetaxel patients with metastatic castration-resistant prostate cancer. We place these data in the context of earlier disease states and other novel agents and explore practical issues concerning the future use of abiraterone.
Authors	Oliver Sartor, Sumanta K Pal
Journal	Nature reviews. Clinical oncology (Nat Rev Clin Oncol) Vol. 10 Issue 1 Pg. 6-8 (Jan 2013) ISSN: 1759-4782 [Electronic] England
PMID	23149889 (Publication Type: Journal Article)
Chemical References	Androstenes Androstenols Taxoids Docetaxel abiraterone Prednisone
Topics	Androstenes Androstenols (therapeutic use) Antineoplastic Combined Chemotherapy Protocols (therapeutic use) Castration Clinical Trials, Phase III as Topic Docetaxel Humans Male Neoplasm Metastasis Prednisone (administration & dosage) Prostatic Neoplasms (drug therapy, pathology) Taxoids (administration & dosage) Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!